Article
Zealand rival to Takeda bowel disease drug hits goal in phase 3
Rating:
0.0
Views:
76
Likes:
1
Library:
1
Zealand's phase 3 short bowel syndrome study hit its primary endpoint, delivering data that could equip it to seek approval for a rival to Gattex.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value